Anthropic Launches AI Tools for Scientific Research and Drug Discovery

Anthropic launched Claude Science on June 30, a dedicated AI research workbench for drugmakers, alongside a new internal drug discovery program targeting neglected diseases, marking the company's most concrete push yet into selling AI tools directly to pharmaceutical and biotech customers . The announcement came at a launch event in San Francisco, where Eric Kauderer-Abrams, Anthropic's head of life sciences, said running its own drug-discovery effort would give the company firsthand experience to build more effective tools for biopharma customers .

Claude Science, currently in beta, is built to unify the fragmented tooling that drug researchers typically juggle across genomics, single-cell RNA sequencing, proteomics, structural biology and cheminformatics. The platform ships with more than 60 pre-configured skills and connectors spanning those domains, along with CRISPR screen design support, letting researchers run multi-step analyses inside a single workspace instead of switching between disconnected databases and file formats . Notably, Claude Science also integrates Basecamp Research's EDEN dataset, a genomic library covering sequencing data from millions of microbe species, which early testers say can compress weeks of pathogen research into a single session . In beta testing, a UCSF epidemiologist reported completing complex glioma genetic-variant analyses in roughly a tenth of the time the work previously took .

Anthropic is backing the beta with up to $30,000 in credits and project funding for qualifying research teams, with applications due July 15 . The move places Claude Science in direct competition with life-sciences tools already fielded by OpenAI's ChatGPT and Google's Gemini, both of which have launched their own dedicated research offerings, intensifying a three-way race among the leading AI labs to become the default platform for computational biology and pharma R&D.

The launch follows Anthropic's April 2026 acquisition of Coefficient Bio, a sub-10-person startup founded by former Genentech computational biologists building AI tooling for drug-pipeline planning, target identification, molecular design, and clinical trial strategy, paid for with roughly $400 million in Anthropic stock . That team, folded into Anthropic's healthcare and life sciences division, gives context for how quickly the company was able to stand up both Claude Science and its internal neglected-disease drug discovery effort.

The timing also feeds into ongoing investor speculation about Anthropic's public listing prospects. A functioning enterprise product with a defined customer base in a high-value vertical like pharma strengthens the commercial narrative Anthropic would need to support a future IPO, even though no listing timeline has been confirmed. Investors and life-sciences customers alike will be watching whether Claude Science's beta cohort converts into paid enterprise contracts, and whether Anthropic's own neglected-disease program produces a credible proof point before competitors' healthcare AI tools mature further.